Targeted hydrophobic anti-tumor drug nanoformulation and preparation method thereof
US11090268B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 24, 2016 |
| Grant date | Aug 17, 2021 |
| Priority date | — |
| Expiry date | Dec 30, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a targeted hydrophobic anti-tumor drug nanoformulation, which comprises a hydrophobic anti-tumor drug and a carrier with a mass ratio of 1:4-32.5, wherein the carrier is composed of 37.5-95.3 wt % albumin and 4.7-62.5 wt % hyaluronic acid-albumin conjugate, and the hyaluronic acid-albumin conjugate is prepared by albumin and hyaluronic acid with a molar ratio of 1:1-20. A preparation method of the nanoformulation comprises: preparing hyaluronic acid-albumin conjugate; formulating carrier solution; formulating drug solution; and preparing nanoformulation. The nanoformulation has even particle size distribution and good dispersibility, is stable without aggregating. The particle size of the lyophilized nanoformulation after being redissolved substantially remains unchanged, the yield of the nanoformulation is high and the efficacy is good after being filtered by a millipore filter (0.22 μm).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.